Nanotechnology Now - Press Release: Early Detection of Pancreatic Cancer Closer Thanks to Multifunctional Nanoparticles

Home > Press > Early Detection of Pancreatic Cancer Closer Thanks to Multifunctional Nanoparticles

Abstract:
Pancreatic cancer has a devastatingly low survival rate (less than 5 percent after 5 years) because it is usually diagnosed at an advanced stage. The initial symptoms, such as pain, jaundice, or weight loss, often do not allow the disease to be caught early enough for surgery and chemotherapy to be effective.

Early Detection of Pancreatic Cancer Closer Thanks to Multifunctional Nanoparticles

Bethesda, MD | Posted on June 27th, 2009

Now, Emory University researchers, led by Lily Yang, M.D., Hui Mao, Ph.D., and Shuming Nie, Ph.D., have created tools for the early diagnosis of pancreatic cancer by attaching a molecule that binds specifically to pancreatic cancer cells to iron oxide nanoparticles that are clearly visible under magnetic resonance imaging (MRI). Tested in mice with implanted human tumors, the particles also can be seen by scanning the mice with a specialized camera because the particles are studded with near-infrared dyes. The properties of the nanoparticles are described in the journal Gastroenterology. Dr. Nie is the principal investigator, and Dr. Yang is a member of the Emory-Georgia Tech Nanotechnology Center for Personalized and Predictive Oncology.

"This work is an early demonstration that nanoparticles can be developed to target pancreatic cancer, opening new opportunities in detecting and treating tumors of low survival rates," said Dr. Nie. "We believe these nanoparticles could be useful tools for detection and localization before surgery, detection of tumor margins and metastases during surgery, and monitoring of the response to therapy," added Dr.Yang. "We are working on multifunctional nanoparticles that could both detect pancreatic tumors by molecular imaging and deliver therapeutic agents in a targeted fashion."

The iron oxide particles have a core that is 10 nanometers in diameter, with a polymer coating. The molecule that allows the particles to discriminate between pancreatic cancer cells and healthy cells is an engineered small protein based on a natural protein found in humans, urokinase plasminogen activator (uPA), which binds to its receptor (uPAR) on cancer cells.

The investigators note that uPA is useful in discriminating tumor cells from regular pancreatic cells irritated by chronic pancreatitis, a challenging task in clinical diagnosis. They found that particles coated with a fragment of uPA are taken up by pancreatic cancer cells and not by normal pancreatic tissue. Tumor endothelial cells, which line blood vessels, also take up the particles, and a low signal is seen in liver and spleen.

Tumors as small as 1 millimeter across can be detected by MRI or optical imaging. The technology now needs to be refined so that it is ready to test in patients. Groups of patients that are at increased risk of pancreatic cancer, such as those with inherited cancer risk factors, chronic pancreatitis, or new-onset diabetes, could benefit.

####

About National Cancer Institute
To help meet the goal of reducing the burden of cancer, the National Cancer Institute (NCI), part of the National Institutes of Health, is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat and prevent cancer.

The NCI Alliance for Nanotechnology in Cancer is a comprehensive, systematized initiative encompassing the public and private sectors, designed to accelerate the application of the best capabilities of nanotechnology to cancer.

Currently, scientists are limited in their ability to turn promising molecular discoveries into benefits for cancer patients. Nanotechnology can provide the technical power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today’s explosion in knowledge.

For more information, please click here

Contacts:
National Cancer Institute
Office of Technology & Industrial Relations
ATTN: NCI Alliance for Nanotechnology in Cancer
Building 31, Room 10A49
31 Center Drive , MSC 2580
Bethesda , MD 20892-2580

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: